Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)

• Mélanie Casile,
• Gilles Albrand,
• Clément Lahaye,
• Benjamin Lebecque,
• Joévin Besombes,
• Céline Bourgne,
• Bruno Pereira,
• Sandrine Saugues,
• Caroline Jamot,
• Eric Hermet,
• Marc G. Berger

Affiliations

Mélanie Casile

Biological Hematology Department, CHU Clermont-Ferrand

Gilles Albrand

Geriatric Evaluation and Management unit, Antoine Charial Hospital

Clément Lahaye

Unité mobile de Gériatrie, CHU Clermont-Ferrand

Benjamin Lebecque

Biological Hematology Department, CHU Clermont-Ferrand

Joévin Besombes

Biological Hematology Department, CHU Clermont-Ferrand

Céline Bourgne

Biological Hematology Department, CHU Clermont-Ferrand

Bruno Pereira

Biostatistics Unit, Clinical Research and Innovation Department, CHU Clermont-Ferrand

Sandrine Saugues

Biological Hematology Department, CHU Clermont-Ferrand

Caroline Jamot

Biological Hematology Department, CHU Clermont-Ferrand

Eric Hermet

Clinical Hematology Department, CHU Clermont-Ferrand

Marc G. Berger

Biological Hematology Department, CHU Clermont-Ferrand